5-Ph-IAA|cas:168649-23-8|西域试剂

5-Ph-IAA,99.57%

产品编号：Bellancom-134653| CAS NO：168649-23-8| 分子式：C₁₆H₁₃NO₂| 分子量：251.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-134653	￥2500.00	杭州北京（现货）
Bellancom-134653	￥4000.00	杭州北京（现货）
Bellancom-134653	￥8000.00	杭州北京（现货）
Bellancom-134653	￥12500.00	杭州北京（现货）
Bellancom-134653	￥18000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

5-Ph-IAA

产品介绍

5-Ph-IAA 是 IAA 的衍生物。5-Ph-IAA 是一种配体与 OsTIR1 (F74G) 突变体一起建立了生长素诱导的 degron 2 系统 (AID2)。AID2 诱导 mAID 融合蛋白的快速有效消耗，从而研究活细胞中的蛋白功能。AID2 可以抑制肿瘤。

生物活性

5-Ph-IAA is a derivative of IAA. 5-Ph-IAA, a ligand, establishes the auxin-inducible degron 2 (AID2) system together with an OsTIR1 (F74G) mutant. AID2 induces rapid and efficient depletion of mAID-fused proteins to study protein function in living cells, causing tumor suppression.

体外研究

HCT116 cells constitutively expressing OsTIR1(F74G) are exposed to 5-Ph-IAA (1 µM; 6 hours), leading to DHC1-mAC degradation, which means the AID2 system better than the original AID system in generating conditional mutant cell lines.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	HCT116 cells
Concentration:	1 µM
Incubation Time:	6 hours
Result:	Depleted DHC1-mAC efficiently in HCT116 cells constitutively expressing OsTIR1(F74G).

体内研究
(In Vivo)

5-Ph-IAA (0-10 mg/kg; intraperitoneally injection; every day; 7 days), used for the AID2 system ,is sufficient to deplete mAID-BRD4 and TOP2A-mAC, leading to tumour suppression.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Balb/c-nu female mice (7 weeks old; 16–20 g ) bearing mAID-BRD4 and TOP2A-mAC xenograft tumours cells
Dosage:	0 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg
Administration:	Intraperitoneally injection; every day; 7 days
Result:	Displayed significant tumour suppression of mAID-BRD4 xenografts and TOP2A-mAC xenografts.

体内研究

5-Ph-IAA (0-10 mg/kg; intraperitoneally injection; every day; 7 days), used for the AID2 system ,is sufficient to deplete mAID-BRD4 and TOP2A-mAC, leading to tumour suppression.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Balb/c-nu female mice (7 weeks old; 16–20 g ) bearing mAID-BRD4 and TOP2A-mAC xenograft tumours cells
Dosage:	0 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg
Administration:	Intraperitoneally injection; every day; 7 days
Result:	Displayed significant tumour suppression of mAID-BRD4 xenografts and TOP2A-mAC xenografts.

体内研究

5-Ph-IAA (0-10 mg/kg; intraperitoneally injection; every day; 7 days), used for the AID2 system ,is sufficient to deplete mAID-BRD4 and TOP2A-mAC, leading to tumour suppression.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Balb/c-nu female mice (7 weeks old; 16–20 g ) bearing mAID-BRD4 and TOP2A-mAC xenograft tumours cells
Dosage:	0 mg/kg, 1 mg/kg, 3 mg/kg and 10 mg/kg
Administration:	Intraperitoneally injection; every day; 7 days
Result:	Displayed significant tumour suppression of mAID-BRD4 xenografts and TOP2A-mAC xenografts.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (397.96 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.9796 mL	19.8981 mL	39.7962 mL
5 mM	0.7959 mL	3.9796 mL	7.9592 mL
10 mM	0.3980 mL	1.9898 mL	3.9796 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (8.28 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (8.28 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (8.28 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (8.28 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
4.

请依序添加每种溶剂： PBS
Solubility: 1 mg/mL (3.98 mM); Clear solution; Need ultrasonic and warming and heat to 60°C